Compare Abbott Laboratories (ABT) vs Enovix Corporation (ENVX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Enovix Corporation — how do they compare? Abbott Laboratories trades at $95.76 (market cap $166.94B), while Enovix Corporation trades at $4.98 (market cap $1.09B). The key difference: Abbott Laboratories is far larger — about 153.2× Enovix Corporation's market cap, and Abbott Laboratories pays a 2.63% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| ABT | ENVX | |
|---|---|---|
Market Cap | $166.94B | $1.09B |
Sector | Health | Technology |
52-Week High | $136.62 | $15.93 |
52-Week Low | $82.57 | $4.84 |
Enterprise Value | $193.69B | $1.10B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ENVX trades at $5.62, up 4.85% today, but technical indicators signal a bearish trend with support at $5 and resistance at $6. The company reported Q1 2026 revenue above guidance and an EPS beat, yet remains unprofitable with a net margin of -499.64%. Analyst consensus is bullish with a $12.75 price target, driven by growth in silicon-anode batteries for AI devices, smart eyewear, and defense markets.
The stock offers high-risk, high-reward potential given its speculative growth story versus persistent losses. Key catalysts include scaling commercial production and smartphone qualification, but execution risks and cash burn require careful monitoring. Investors should weigh analyst optimism against fundamental challenges in the competitive battery sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
